Western Wealth Management LLC Buys 4,461 Shares of Alphatec Holdings, Inc. $ATEC

Western Wealth Management LLC lifted its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 5.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 91,511 shares of the medical technology company’s stock after purchasing an additional 4,461 shares during the quarter. Western Wealth Management LLC owned 0.06% of Alphatec worth $1,016,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Teacher Retirement System of Texas acquired a new position in Alphatec in the first quarter valued at about $158,000. Envestnet Asset Management Inc. increased its holdings in shares of Alphatec by 1.2% during the first quarter. Envestnet Asset Management Inc. now owns 390,414 shares of the medical technology company’s stock worth $3,959,000 after buying an additional 4,754 shares in the last quarter. CWM LLC raised its stake in shares of Alphatec by 67.2% in the first quarter. CWM LLC now owns 31,336 shares of the medical technology company’s stock valued at $318,000 after acquiring an additional 12,598 shares during the last quarter. Larson Financial Group LLC acquired a new position in shares of Alphatec in the 1st quarter worth approximately $54,000. Finally, Legato Capital Management LLC acquired a new position in shares of Alphatec in the 1st quarter worth approximately $600,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Trading Up 0.7%

ATEC stock opened at $19.87 on Tuesday. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a twelve month low of $8.18 and a twelve month high of $21.16. The company has a market cap of $2.95 billion, a P/E ratio of -17.58 and a beta of 1.17. The business has a fifty day moving average of $16.13 and a 200-day moving average of $13.98.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to the consensus estimate of $182.78 million. Alphatec’s revenue was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling at Alphatec

In related news, Director David R. Pelizzon sold 250,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00. Following the transaction, the director directly owned 11,145,045 shares in the company, valued at $231,816,936. This represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Patrick Miles sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $18.96, for a total transaction of $1,896,000.00. Following the completion of the transaction, the chief executive officer directly owned 5,364,078 shares in the company, valued at approximately $101,702,918.88. The trade was a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,828,823 shares of company stock valued at $33,815,195 over the last 90 days. Company insiders own 20.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on ATEC. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. Lake Street Capital set a $25.00 price target on Alphatec and gave the company a “buy” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alphatec in a research report on Tuesday, November 11th. Finally, Needham & Company LLC increased their price objective on shares of Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and an average price target of $22.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.